PharmaEssentia Resolves to File for Annulment of Second Partial Arbitral Award at Frankfurt Higher Regional Court, Germany

1. Parties to the Legal Proceeding: Claimant: PharmaEssentia Corporation Respondent: AOP Orphan Pharmaceuticals GmbH (abbreviated as AOP)

2. Court or Administrative Authority Involved: Frankfurt Higher Regional Court, Germany

3. Case Reference Number: ICC Case No. 25808/PTA/XZG

4. Date of Occurrence: 115/08/10

5. Background (Including Subject of Dispute): Regarding the arbitration case between the Company and AOP, the Company received the Second Partial Final Award from the International Chamber of Commerce (ICC) International Court of Arbitration on August 7, 2026. The Company's Board of Directors has resolved to file a petition with the Frankfurt Higher Regional Court in Germany to annul the aforementioned arbitral award.

6. Handling Process: The Second Partial Final Award is closely related to the first-stage award and potentially infringes upon the Company’s right to be heard. To safeguard the interests of the Company and all shareholders, the Company intends to file a lawsuit seeking annulment of the second partial arbitral award with the Frankfurt Higher Regional Court within the statutory period.

7. Impact on Company's Financials and Operations, and Estimated Financial Impact: Currently, there is no impact on the Company’s financials or operations.

8. Countermeasures and Improvement Status: The Company’s Board of Directors has resolved to file for the annulment of the Second Partial Final Award with the Frankfurt Higher Regional Court in Germany.

9. Other Matters to be Disclosed (If the entity involved in the event or resolution is a publicly listed company or above, this material information also qualifies as a matter under Article 7, Paragraph 2, Item 2 of the Enforcement Rules of the Securities and Exchange Act that significantly affects shareholder rights or securities prices): None.

Keywords: Material Information